23 February 2017

Notice of Results

RNS Number : 6404X Verona Pharma PLC 23 February 2017

Read more

23 February 2017

Notice of Results

RNS Number : 6404X

Read more

22 February 2017

First COPD patient dosed with RPL554

RNS Number : 4893X Verona Pharma PLC 22 February 2017

Read more

13 February 2017

Total Voting Rights & Block Listing Interim Review

RNS Number : 6715W Verona Pharma PLC 13 February 2017

Read more

8 February 2017

Result of General Meeting and Share Consolidation

RNS Number : 3641W Verona Pharma PLC 08 February 2017

Read more

18 January 2017

Publication of Circular

RNS Number : 4091U Verona Pharma PLC 18 January 2017

Read more

11 January 2017

Holding(s) in Company

RNS Number : 8462T Verona Pharma PLC 11 January 2017

Read more

4 January 2017

Holding(s) in Company

Read more

29 December 2016

VERONA PHARMA PLC - Issue of Equity

PR Newswire

Read more

23 November 2016

VERONA PHARMA PLC - Registered Initial Public Offering in the US

PR Newswire

Read more

Innovative Therapies for Respiratory Care

See the 2017 Verona Pharma corporate video 2017

Runtime: 04:05

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us